Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.53 |
| ▸ | UMPS | P11172 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 14/20 | 0.45 |
| ▸ | IMPDH1 | P20839 | 10/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiazofurin SCHEMBL1651851 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL4287 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL7169632 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL23848843 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL2883659 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL23264566 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL13109276 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL2883657 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| SCHEMBL7832887 | 0.89 | PYGL (0.53) | PYGLUMPS | |
| SCHEMBL23375983 | 0.88 | PYGL (0.43) | PYGLIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217014-B2 | Pharmaceutical composition for treatment of blood clotting disorder | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20090232769-A1 | Pharmaceutical Composition For Treatment Of Blood Clotting Disorder | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090232769-A1 | Pharmaceutical Composition For Treatment Of Blood Clotting Disorder | SERPINC1, F2, F8 | PYGL 134/4885UMPS 1334/4885IMPDH2 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.